SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: buffalodon20031/9/2008 10:36:41 PM
   of 370
 
Does any interested parties in Vion have any constructive comments regarding the FDA's approval to resume phase III that was in a halt status? Due to stock's slow drop off to below $1, delisting is imminent within year; consequently, mgmt has scheduled meetings to vote a reverse split (1 to 5 up to 1 to 10). However, this info came out in early January prior to yesterday's FDA resumption approval. Obviously, the yahoo board has many positive runnup posts with some that believe that FDA approval to resume will not prevent stock from hitting $1 by mid February. The reverse split does not favor the investor. Obviously, sell targets have to be pushed up, maybe unrealistic, even with possible FDA approval by 2009. Any thoughts??? I hold 4500 shares and don't like outcomes if reverse split realized.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News